Muhammad Absar, et al. “CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML”. Journal of Population Therapeutics and Clinical Pharmacology, vol. 29, no. 02, Feb. 2022, pp. 311-20, https://doi.org/10.53555/jptcp.v29i02.4161.